New antibody drug targets Hard-to-Treat cancers
NCT ID NCT06178614
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This early-phase study tests a new drug called JNJ-87890387 in people with advanced solid tumors that have spread or cannot be removed. The drug is designed to help the immune system attack cancer cells. The main goals are to find a safe dose and to check for side effects. About 200 adults with certain types of kidney, ovarian, uterine, colorectal, or lung cancer may join.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Leon Berard
RECRUITINGLyon, 69008, France
-
Hosp Univ Vall D Hebron
RECRUITINGBarcelona, 08035, Spain
-
Hosp. Univ. 12 de Octubre
RECRUITINGMadrid, 28041, Spain
-
Institut Gustave Roussy
RECRUITINGVillejuif, 94805, France
-
Sarah Cannon Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
-
Start Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple screening program could transform cancer aftercare
- A new program aims to ease the 'Lost in Transition' struggle for cancer survivors
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a pill outsmart Tumors' defenses?
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can we predict who needs extra therapy after kidney cancer surgery?